India : Pfizer to offer 50 million doses and Moderna jab likely in 2022
While Moderna has conveyed to Indian authorities that it does not have surplus vaccines to share in 2021, there are limited prospects of Johnson & Johnson exporting its jabs from the US to other countries in the near future, the people added.
Moderna is expecting to launch a single-dose Covid-19 vaccine in India next year and is in talks with Cipla among other Indian firms, while another US giant Pfizer is ready to offer (50 million) five crore shots in 2021 itself but it wants significant regulatory relaxations including indemnification, people familiar with the matter said.
Two rounds of high-level meetings chaired by the Cabinet Secretary were held last week on the availability of vaccines in the global as well as domestic markets as it was felt that there is an urgent need to procure the jabs at a time the country is reeling under an unprecedented second wave of COVID-19 and a widening gap between supply and requirement.
Currently, the country is using two ‘made-in India’ jabs Covishield and Covaxin to inoculate its billion-plus population and has administered 200 million doses since launching the world’s largest vaccination drive in mid-January. A third vaccine, Russian-made Sputnik V, has been approved by the government and is being used on a smaller scale at present.